AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses …
AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses …
China has seen a rise in ongoing clinical trials for the past few years which has now surpassed the US, …
US-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III …
GenSight’s gene therapy treatment for patients living with Leber hereditary optic neuropathy (LHON) has demonstrated sustained efficacy and eyesight improvement …
US-based biopharmaceutical company Spinogenix has published top line outcomes from a Phase II trial of SPG601 for treating Fragile X …
US-based biotechnology company Rallybio has dosed the first subject in a Phase II trial evaluating RLYB212 as a potential treament …
Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that was the takeaway from …
As President Trump’s tariff restrictions are imposed on China, the pharmaceutical industry has been deciphering how it will be impacted …
A US federally funded Phase II challenge trial investigating AbViro’s sole pipeline candidate, AV1, will see 84 patients infected with …
Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the world due to factors such …
Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years …
Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it …
Satellos Bioscience has concluded the enrolment of subjects for all four multiple-ascending dose (MAD) cohorts for the Phase I trial …
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of differentiation 19 (CD19)-directed …
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the company …